Ivabradine Versus Digitalis Glycosides in Heart Failure With Reduced Ejection Fraction: A Comparative Appraisal of Two Additional Medical Therapies
Abstract Purpose Resting heart rate predicts outcome in heart failure (HF) with reduced ejection fraction (HFrEF), but lowering it benefits only hemodynamically stable patients. This narrative review compares ivabradine and the digitalis glycosides, the only additional medical therapies in the 2026 ESC guidelines that slow the heart rate, as add-ons to foundational medical therapy (FMT). Methods We searched PubMed and the Cochrane Library through August 2026 and current guidelines, giving greatest weight to large randomized trials and contemporary meta-analyses. Results Ivabradine reduced cardiovascular death or heart-failure hospitalization (HR 0.82, 95% CI 0.75–0.90) without a mortality benefit; it is restricted to sinus rhythm with LVEF ≤ 35% and heart rate ≥ 70 bpm (Class IIa B1). The digitalis glycosides act in any rhythm, with LVEF ≤ 40% (Class IIa B1), and reduce worsening-heart-failure events (pooled HR 0.75, n = 9,013) without affecting mortality, within narrow, agent-specific therapeutic windows (digoxin 0.5–0.9 ng/mL; digitoxin 8–18 ng/mL). DIGIT-HF (digitoxin) was positive and DECISION (digoxin) neutral; their estimates are similar in direction and magnitude, but differences in drug, population and endpoint preclude calling them concordant. Digoxin withdrawal is associated with deterioration, although contemporary data rest on few events. Conclusion Ivabradine and the digitalis glycosides are not symmetric alternatives. Ivabradine is a narrow add-on for sinus-rhythm patients who remain tachycardic despite beta-blockade; the glycosides serve both ventricular rate control in atrial fibrillation and prevention of worsening HF irrespective of rhythm. Both reduce morbidity rather than mortality and belong only after FMT is optimized. No randomized trial has compared them directly.
Authors
- Luca Fazzini (ORCID: https://orcid.org/0000-0003-2407-7435)
- Gregorio Tersalvi (ORCID: https://orcid.org/0000-0003-1845-1777)
- Mattia Arrigo (ORCID: https://orcid.org/0000-0003-4028-2869)
- Marco Bergonti (ORCID: https://orcid.org/0000-0001-9864-1938)
- Vittorio Beltrani (ORCID: https://orcid.org/0009-0005-4235-6544)
- Giordano Maria Pugliesi (ORCID: https://orcid.org/0009-0008-6770-1414)
- Martin R. Gruebler
Institutions
- Sigmund Freud Privatuniversität Wien (AT)
- Danube Private University (AT)
- Mayo Clinic (US)
- Medical University of Graz (AT)
- Ente Ospedaliero Cantonale (CH)
- Ospedale Papa Giovanni XXIII (IT)
- Ospedale Regionale di Mendrisio (CH)
- Azienda Ospedaliera San Gerardo (IT)
- Universitätsklinikum Wiener Neustadt (AT)
- Istituto Cardiocentro Ticino (CH)
- Università della Svizzera italiana (CH)
Publication Details
- Journal
- Cardiovascular Drugs and Therapy
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1007/s10557-026-07989-x
- Primary Topic
- Heart rate and cardiovascular health
- Type
- article
- Field-Weighted Citation Impact
- 0.00